27例携带T315I BCR-ABL突变的甲磺酸伊马替尼耐药慢性髓性白血病患者的临床结局
Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.
作者信息
Nicolini Franck E, Hayette Sandrine, Corm Selim, Bachy Emmanuel, Bories Dominique, Tulliez Michel, Guilhot François, Legros Laurence, Maloisel Frédéric, Kiladjian Jean-Jacques, Mahon François-Xavier, Lê Quoc-Hung, Michallet Mauricette, Roche-Lestienne Catherine, Preudhomme Claude
机构信息
Hematology Department, Hôpital E. Herriot, Lyon, France.
出版信息
Haematologica. 2007 Sep;92(9):1238-41. doi: 10.3324/haematol.11369.
We analyzed 27 CML patients treated with imatinib (IM) who developed a BCR-ABLT315I mutation. These patients had poor prognostic features: High or intermediate Sokal index (82%), and lack of CCyR under IM (59%). At T315I discovery, patients were in advanced phase (59%), with clonal evolution (84%). Median time since diagnosis was 39 months, and progression occurred 13 months after IM initiation, regardless of disease phase. Overall survival since IM initiation was 42.5 months for chronic, and 17.5 months for advanced phases, and all patients progressed. This mutation seems related to or (partially?) responsible for progression and poor survival.
我们分析了27例接受伊马替尼（IM）治疗且发生BCR-ABL T315I突变的慢性髓性白血病（CML）患者。这些患者具有不良预后特征：高或中度索卡尔指数（82%），且在伊马替尼治疗下缺乏完全细胞遗传学缓解（CCyR，59%）。在发现T315I突变时，患者处于晚期（59%），伴有克隆演变（84%）。自诊断以来的中位时间为39个月，无论疾病阶段如何，进展均发生在开始使用伊马替尼13个月后。自开始使用伊马替尼以来，慢性期患者的总生存期为42.5个月，晚期患者为17.5个月，所有患者均出现疾病进展。这种突变似乎与疾病进展和生存不良有关或（部分？）是其原因。
Zotero 插件